Therapure Launches Biologics Division
Therapure Biopharma, a Mississauga, Ontario, Canada-based biologics manufacturer, has launched its plasma products and technology division as Evolve Biologics, focused on plasma-derived therapeutics for patients with rare chronic diseases and acute conditions.
Evolve’s proprietary PlasmaCap EBA is a technology for capture of plasma proteins at higher yields and purities from human blood plasma, according to information from Therapure. The technology uses expanded bed adsorption (EBA) chromatography to capture plasma proteins directly from plasma or fractionated plasma materials without the use of cold ethanol. As of now, the company has two major proteins, intravenous immunoglobulin and albumin, advancing in development.
Evolve’s leadership team consists of Chief Executive Officer (CEO) Blaine Forshage; Chief Commercial Officer, David Holliday; and Chief Financial Officer, Gregory Gould.
As CEO, Forshage brings 25 years of experience in the healthcare and biologics market, with over 17 years at Baxter/Baxalta, most recently as North American Region Head (General Manager) for Baxalta. Following his early career in sales, he served in multiple positions of increasing responsibility for Baxter/Baxalta and launched several brands in the plasma and hemophilia marketplace.
David Holliday brings over 30 years of pharmaceutical and biologics experience. He has launched and commercialized several brands, including ones in the UK, US, and global markets, most recently as Vice President, Commercial Operations for Octapharma US. Prior to that, he was the Global Vice President of Marketing Operations & Hemophilia for Baxter BioScience and also ran its UK Bioscience Business, following a 17-year career with Novartis.
Gregory Gould has over 20 years of business experience in the biotech and life-sciences market, including 17 years as a public company CFO at several NASDAQ- and NYSE-listed companies. He has closed on several transactions, including in-licensing and out-licensing of products, buying and selling of products and divisions, and the sale of three publicly traded companies. Gould started his career at Arthur Andersen and is a certified professional accountant.
Source: Therapure Biopharma